BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 29195602)

  • 1. Reduction of body iron in HFE-related haemochromatosis and moderate iron overload (Mi-Iron): a multicentre, participant-blinded, randomised controlled trial.
    Ong SY; Gurrin LC; Dolling L; Dixon J; Nicoll AJ; Wolthuizen M; Wood EM; Anderson GJ; Ramm GA; Allen KJ; Olynyk JK; Crawford D; Ramm LE; Gow P; Durrant S; Powell LW; Delatycki MB
    Lancet Haematol; 2017 Dec; 4(12):e607-e614. PubMed ID: 29195602
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Should HFE p.C282Y homozygotes with moderately elevated serum ferritin be treated? A randomised controlled trial comparing iron reduction with sham treatment (Mi-iron).
    Ong SY; Dolling L; Dixon JL; Nicoll AJ; Gurrin LC; Wolthuizen M; Wood EM; Anderson GJ; Ramm GA; Allen KJ; Olynyk JK; Crawford D; Kava J; Ramm LE; Gow P; Durrant S; Powell LW; Delatycki MB
    BMJ Open; 2015 Aug; 5(8):e008938. PubMed ID: 26270952
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rusfertide for the treatment of iron overload in HFE-related haemochromatosis: an open-label, multicentre, proof-of-concept phase 2 trial.
    Kowdley KV; Modi NB; Peltekian K; Vierling JM; Ferris C; Valone FH; Gupta S
    Lancet Gastroenterol Hepatol; 2023 Dec; 8(12):1118-1128. PubMed ID: 37863080
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased risk of death from iron overload among 422 treated probands with HFE hemochromatosis and serum levels of ferritin greater than 1000 μg/L at diagnosis.
    Barton JC; Barton JC; Acton RT; So J; Chan S; Adams PC
    Clin Gastroenterol Hepatol; 2012 Apr; 10(4):412-6. PubMed ID: 22265917
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Effectiveness of therapeutic erythrocytapheresis to achieve iron depletion in hereditary type 1 hemochromatosis: report of 30 cases].
    Poullin P; Lefèvre PA
    Transfus Clin Biol; 2011 Dec; 18(5-6):553-8. PubMed ID: 22019606
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Erythrocytapheresis versus phlebotomy in the initial treatment of HFE hemochromatosis patients: results from a randomized trial.
    Rombout-Sestrienkova E; Nieman FH; Essers BA; van Noord PA; Janssen MC; van Deursen CT; Bos LP; Rombout F; van den Braak R; de Leeuw PW; Koek GH
    Transfusion; 2012 Mar; 52(3):470-7. PubMed ID: 21848963
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Diagnosis of 5 patients with possible primary hemochromatosis].
    Jacobs EM; de Vries RA; Elving LD; Stalenhoef AF; Swinkels DW
    Ned Tijdschr Geneeskd; 2003 Apr; 147(14):666-70. PubMed ID: 12712652
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HFE p.C282Y homozygosity predisposes to rapid serum ferritin rise after menopause: A genotype-stratified cohort study of hemochromatosis in Australian women.
    Warne CD; Zaloumis SG; Bertalli NA; Delatycki MB; Nicoll AJ; McLaren CE; Hopper JL; Giles GG; Anderson GJ; Olynyk JK; Powell LW; Allen KJ; Gurrin LC;
    J Gastroenterol Hepatol; 2017 Apr; 32(4):797-802. PubMed ID: 27784128
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hemochromatosis and iron-overload screening in a racially diverse population.
    Adams PC; Reboussin DM; Barton JC; McLaren CE; Eckfeldt JH; McLaren GD; Dawkins FW; Acton RT; Harris EL; Gordeuk VR; Leiendecker-Foster C; Speechley M; Snively BM; Holup JL; Thomson E; Sholinsky P;
    N Engl J Med; 2005 Apr; 352(17):1769-78. PubMed ID: 15858186
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MRI-Based Iron Phenotyping and Patient Selection for Next-Generation Sequencing of Non-Homeostatic Iron Regulator Hemochromatosis Genes.
    Viveiros A; Schaefer B; Panzer M; Henninger B; Plaikner M; Kremser C; Franke A; Franzenburg S; Hoeppner MP; Stauder R; Janecke A; Tilg H; Zoller H
    Hepatology; 2021 Nov; 74(5):2424-2435. PubMed ID: 34048062
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum ferritin concentration predicts hepatic fibrosis better than hepatic iron concentration in human HFE-Haemochromatosis.
    Wood MJ; Crawford DHG; Wockner LF; Powell LW; Ramm GA
    Liver Int; 2017 Sep; 37(9):1382-1388. PubMed ID: 28231420
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Iron-overload-related disease in HFE hereditary hemochromatosis.
    Allen KJ; Gurrin LC; Constantine CC; Osborne NJ; Delatycki MB; Nicoll AJ; McLaren CE; Bahlo M; Nisselle AE; Vulpe CD; Anderson GJ; Southey MC; Giles GG; English DR; Hopper JL; Olynyk JK; Powell LW; Gertig DM
    N Engl J Med; 2008 Jan; 358(3):221-30. PubMed ID: 18199861
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Erythrocytapheresis compared with whole blood phlebotomy for the treatment of hereditary haemochromatosis.
    Sundic T; Hervig T; Hannisdal S; Assmus J; Ulvik RJ; Olaussen RW; Berentsen S
    Blood Transfus; 2014 Jan; 12 Suppl 1(Suppl 1):s84-9. PubMed ID: 24333062
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Course of iron parameters in HFE-hemochromatosis patients during initial treatment with erythrocytapheresis compared to phlebotomy.
    Rombout-Sestrienkova E; Koek GH; Neslo R; van Kraaij M; Menheere PP; Masclee A; Swinkels DW
    J Clin Apher; 2016 Dec; 31(6):564-570. PubMed ID: 26878994
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EASL Clinical Practice Guidelines on haemochromatosis.
    ;
    J Hepatol; 2022 Aug; 77(2):479-502. PubMed ID: 35662478
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HFE C282Y homozygosity is associated with lower total and low-density lipoprotein cholesterol: The hemochromatosis and iron overload screening study.
    Adams PC; Pankow JS; Barton JC; Acton RT; Leiendecker-Foster C; McLaren GD; Speechley M; Eckfeldt JH
    Circ Cardiovasc Genet; 2009 Feb; 2(1):34-7. PubMed ID: 20031565
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The modified iron avidity index: a promising phenotypic predictor in HFE-related haemochromatosis.
    Verhaegh PL; Moris W; Koek GH; van Deursen CT
    Liver Int; 2016 Oct; 36(10):1535-9. PubMed ID: 26992127
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence of HFE-related haemochromatosis and secondary causes of hyperferritinaemia and their association with iron overload in 1059 French patients treated by venesection.
    Le Gac G; Scotet V; Gourlaouen I; L'Hostis C; Merour MC; Karim Z; Deugnier Y; Bardou-Jacquet E; Lefebvre T; Assari S; Ferec C
    Aliment Pharmacol Ther; 2022 Apr; 55(8):1016-1027. PubMed ID: 35122291
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlates of hepcidin and NTBI according to HFE status in patients referred to a liver centre.
    Ryan E; Ryan JD; Russell J; Coughlan B; Tjalsma H; Swinkels DW; Stewart S; Crowe JP
    Acta Haematol; 2015; 133(2):155-61. PubMed ID: 25277871
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.